Table 2.
Immunohistochemical expression of HER family members and their co-expressions in 144 mCRC patients treated with anti-EGFR cetuximab.
| Variables | No. of Positive Tumours (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| % Positive Tumour Cells | Intensity | Location | |||||||||
| >5 | >10 | >20 | >50 | 1+ | 2+ | 3+ | Mem | Cyto | Nuc | ||
| EGFR | 36 | 28 | 17 | 8 | 26 | 15 | 2 | 31 | 14 | - | |
| (25) | (19) | (12) | (6) | (18) | (10) | (1) | (22) | (10) | |||
| HER2 | 139 | 125 | 103 | 89 | 90 | 37 | 8 | 39 | 100 | - | |
| (97) | (87) | (72) | (62) | (63) | (26) | (6) | (27) | (69) | |||
| HER3 | 114 | 79 | 55 | 29 | 67 | 38 | 10 | 70 | 43 | - | |
| (79) | (55) | (38) | (20) | (47) | (26) | (7) | (49) | (30) | |||
| HER4 | 69 | 59 | 34 | 14 | 67 | 2 | 0 | 4 | 27 | 38 | |
| (48) | (41) | (24) | (10) | (47) | (1) | (0) | (3) | (19) | (26) | ||
| Co-expression of HER family (%) | |||||||||||
| EGFR | EGFR | EGFR | HER2 | HER2 | HER3 | EGFR | EGFR | EGFR | HER2 | EGFRHER2 | |
| HER2 | HER3 | HER4 | HER3 | HER4 | HER4 | HER2HER3 | HER2HER4 | HER3HER4 | HER3HER4 | HER3HER4 | |
| 34 | 29 | 17 | 109 | 68 | 57 | 27 | 15 | 18 | 56 | 15 | |
| (24) | (20) | (12) | (76) | (47) | (40) | (19) | (10) | (13) | (39) | (10) | |
Mem, Membranous; Cyto, Cytoplasmic; Nuc, Nuclear.